引文
[1] 瞿文,陈庆华,赵瑞钦,等.丙氨瑞林生物可降解缓释微球注射剂的研究[J].中国医药工业杂志,2000,31(1):14-18.
[2] 俞媛,高申,钟延强,等.布比卡因聚乳酸缓释微球在家兔体内药动学研究[J].中国药学杂志,2002,37(11):849-852.
[3] 李凤前,陆彬,陈文彬,等.肺靶向汉防己甲素缓释微囊的小鼠体内分布[J].中国医院药学杂志,2001,21(5):259-261.
[4] 陈军,易以木,杨希雄,等.胰岛素聚乳酸纳米粒的初步研究[J].华西药学杂志,2002,17(4):272-273.
[5] 尹宗宁,陆彬.注射用胰岛素缓释纳米囊的研究[J].中国医药工业杂志,2000,31(8):349-352.
[6] 张蜀,谭载友,陈济民.可生物降解盐酸多西环素缓释凝胶的含量测定[J].中国新药杂志,2001,10(6):439-441.
[7] 赵锋,高永良.乳化分散法制备聚乳酸微球的研究进展[J].中国新药杂志,2002,11(2):123-126.
[8] Bostman OM. Current concept review absorbable impiants for the fixation of fracture [J]. J Bone Joint Surg, 1991,73(1):148.
[9] S.M. Herbig ,J.R. Cardinal, R.W. Korsmeyer .Asymmetric-membrane tablet coatings forosmotic drug delivery. J Control Release, 1995, (35) 127-136.
[10] Yong Gan,Weisan Pan,Mingchun Wei. Cyclodextrin complex osmotic pump tablet forglipizide delivery . Drug Dev Ind Pharm, 2002, 28(8):1015-1021.
[11] K. Okimoto, R.A. Rajewski, V.J. Stella .Release of testosterone from an osmotic pump tabletutilizing (SBE)7m-β-CD as both a solubilizer and osmotic agent . J Control Release, 1999,(58):29-38.
[12] K. Okimoto, M. Miyake, N. Ohnishi, R.A, et al Design and Evalulation of an osmotic pumptablets for chlorpromazing using (SBE)7m-β-CD. Pharm Res, 1999,16:1562-1568.
[13] K. Okimoto, R.A. Rajewski, V.J. Stella. Factors affecting membrane-controlled drug release for an osmotic pump tablets(OPT) utilizing (SBE)7m-β-CD as both a both a solubilizer and osmotic agent. J Control Release, 1999, 60:311-319.
[14] Ouyang D, Nie S, Li W, Guo H, Liu H, Pan W Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets. J Pharm Pharmacol. 2005,57(7):817-820.
[15] Casnda E, Harcoss P, Bacsy Z, Berghammer R.Ten years of experience with Cavinton. Drug Dev Res, 1988,14:185-187.
[16] 张杰文,刘忠祥.长春西汀治疗急性脑梗死50例.医药导报,2003,22(2):92.
[17] 花放 李绍英.国产长春西汀治疗脑梗塞恢复期75例.中国新药杂志,1994,3:40-41.
[18] Tohgi H, Sasaki K, Chiba K, Nozaki Y. Effect of vinpocetine on oxygen release of hemoglobinand erythrocyte organic polyphosphate concentrations in patients with vascular dementia of theBinswanger type. Arzneim Forsch, 1990,40(6): 640-643.
[19] Hayakawa M. Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on redblood cell deformability. Arzneimittelforschung, 1992,42(2): 108-110.
[20] Hayakawa, M. Effect of vinpocetine on red blood cell deformability in stroke patients.Arzneimittelforschung, 1992,42(4), 425-427.
[21] Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemicstroke.Eur J Clin Pharmacol. 1999,55(5): 349-352.
[22] 陈鹰,李高,王瑞华,汤韧.长春西汀固体分散体的制备及体外溶出特性.中国医院药学杂志,2006,5:559-562.
[23] Chilko D, Howard S. On the analysis of dissolution rate. Drug Dev Ind Pharm,1986,12 (7) :969-992.
[24] Shah VP, Tsong Y, Sathe P, et al. In vitro dissolution profile comparison-statistics and analysisof the similarity factor f_2. Pharm Res, 1998,15(6) : 889-896.
[25] Gohel MC, Panchal MK. Novel use of similarity factors f_2 and Sd for the development ofdiltiazem HCL modified-release tablets using a 32 factorail design . Drug Dev Ind Pharm, 2002,28(1): 77-87.
[26] Gabrielsson J, Nystrom A, Lundstedt T. Application of Multivariate analysis in pharmaceuticaldevelopment work . Drug Dev Ind Pharm, 2000, 26(3): 275-296.
[27] 程刚主编.FDA生物药剂学指南.沈阳:沈阳药科大学,2001年3月
[28] Center for Drug Evaluation and Research, FDA. Guidance for industry bioavailability and bioequivalences studies for orally administered drug products: General considerations, 1999: 10-14.
[29] 聂淑芳,潘卫三,李伟.长春西汀的大鼠在体肠吸收研究.中国医药工业杂志.2005,36(10):625-628
[30] Rajan K. Verma, Divi Murali Krishna, Sanjay Garg. Formulation aspects in the developmentof osmotically controlled oral drug delivery systems. J. Control. Release, 2002, 79: 7-27.
[31]Shively, M.L., Bennett, A.T., Coonts, B.A., Renner, W.D., Southard, J.L., Physico-chemicalcharacterization of polymer injectable implant delivery system. J. Control Release 33, 237-243(1995).
[32] Ritger R.L.Peppas, NA. Asimple equation for description of solute release I Fickian andnon-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs[J].J Control. Release. 1987,
[33] Iskandarani B, Clair JH, Patel P,et al. Simultane-ous optimization of capsule and tabletformulationusing response surface methodology[J].Drug Dev Ind Pharm, 1993,19(16):2089-2101.
[34] Abu-Izza KA, Garcia-Contreras L, Lu DR.Prepara-tion and evaluation of sustained releaseAZT-loadedmicrospheres: optimization of the release character-istics using response surfacemethodology [J].JPharm Sci, 1996, 85(2):144-149.
[35]Abu-Izza KA, Garcia-Contreras L, Lu DR. Prepara-tion and evaluation of zidovudine-loadedsustained-release microspheres. 2. Optimization of multipleresponse variable[J].J Pharm Sci, 1996,85(6):572-576.
[36]吴伟 崔光华; 星点设计-效应面优化法及其在药学中的应用;Foreign Medical ScienceSection on Pharmacy 2000 Oct;27(5)
[37] Langenbucher F, Numerical convolution/deconvolutinon as a tool for correlating in vitro with in vivo drug availability[J]. Pharm Ind. 1982, 44(11): 1166-1172.
[38] Sampath Suchitra S, Garvin Kevin, Robinson Dennis H. Preparation and characterization of biodegradable PLLA gentamicin delivery systems. Int J Pharm, 1992,78 (2-3):165-174
[39] Skelly IP, Amidon GL, Barr WH, et al. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage form[J]. Pharm Res. 1990, 7(9): 975.
[40] Balan G, Timmins P, Greene DS, et al. In vitro-in vivo correlation models for metformin after administration of modified-release oral dosage forms to healthy human volunteers[J]. J Pharm Sci. 2001. 90(8): 1176-1185.
[41]郑梁元.控释制剂中体内外相关性研究的两种方法[J].中国药科大学学报,1994,25(4):214-217.
[42]李凌冰,张娜,邓树海.应用体内外相关性模型研究红霉素缓释胶囊的体内外相关性[J].中国药学杂志,2004,39(2):127-129.
[43]Fracis NM. A comparison of six deconvolution technique[J]. J Pharmcoki Biopharm. 1996, 24:283.
[44]Krol GJ, Lettieri JT, Yeh SC, et al. Disposition and pharmacokinetics of 14C-nitrendipine in healthy volunteers[J].J Cardiovasc Pharmacol. 1987,6:S122-S128.
[45]Kiwada H, Morito K, Hayashi M, S. Awazu, M. Hanano, A new numerical calculation method for deconvolution in linear compartment analysis of pharmacokinetics[J]. Chem Pharm Bull, 1977, 25: 1312-1318.
[46] 聂淑芳,李威,杨星钢,潘卫三.长春西汀凝胶骨架片中枸橼酸和介质pH值对药物释放的影响.中国药学杂志.2004 39(6):442-446.
[47] 聂淑芳,刘志东,彭缨.长春西汀海藻酸钠骨架片体外释药影响因素研究.沈阳药科大学学报,2004 21(2):91-96.
[48]郑梁元.控释制剂中体内外相关性研究的两种方法[J].中国药科大学学报,1994,25(4):214-217.
[49]李凌冰,张娜,邓树海.应用体内外相关性模型研究红霉素缓释胶囊的体内外相关性[J].中国药学杂志,2004,39(2):127-129.
[50]Kiwada H, Morito K, Hayashi M, S. Awazu, M. Hanano, A new numerical calculation method for deconvolution in linear compartment analysis of pharmacokinetics[J]. Chem Pharm Bull, 1977, 25: 1312-1318.